These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 2498049)

  • 1. The status of nuclear medicine techniques in the diagnosis of bone metastases in breast cancer.
    Makaiová I; Kausitz J; Hupka S; Michaliková B; Vivodová M; Bohunický L
    Czech Med; 1989; 12(1):34-9. PubMed ID: 2498049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of combination of bone scanning and measurement of carcinoembryonic antigen in diagnosis of breast cancer metastases.
    Kausitz J; Makaiová I; Hupka S; Vivodová M
    Czech Med; 1981; 4(3):159-62. PubMed ID: 7307849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between bone scintigraphy and tumor markers in patients with breast cancer.
    Yildiz M; Oral B; Bozkurt M; Cobaner A
    Ann Nucl Med; 2004 Sep; 18(6):501-5. PubMed ID: 15515750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy.
    Nicolini A; Ferrari P; Sagripanti A; Carpi A
    Br J Cancer; 1999 Mar; 79(9-10):1443-7. PubMed ID: 10188888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations.
    Nicolini A; Carpi A; Ferrari P; Pieri L
    Tumour Biol; 2003; 24(6):275-80. PubMed ID: 15004486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
    Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
    Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients.
    Zissimopoulos A; Matthaios D; Matthaiou E; Mantadakis E; Karaitianos I
    J BUON; 2007; 12(4):505-11. PubMed ID: 18067209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
    Gedik GK; Kiratli PO; Tascioglu B; Aras T
    Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers?
    Buffaz PD; Gauchez AS; Caravel JP; Vuillez JP; Cura C; Agnius-Delord C; Fagret D
    Eur J Nucl Med; 1999 Jan; 26(1):8-11. PubMed ID: 9933655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between CEA, TPA, CA 15/3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer.
    Francini G; Montagnani M; Petrioli R; Paffetti P; Marsili S; Leone V
    Int J Biol Markers; 1990; 5(2):65-72. PubMed ID: 2283479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of non-staging skeletal scintigraphy in breast cancer.
    Kunkler IH; Merrick MV
    Clin Radiol; 1986 Nov; 37(6):561-2. PubMed ID: 3098492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma.
    Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Skopljak A
    Bosn J Basic Med Sci; 2006 Feb; 6(1):75-7. PubMed ID: 16533185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions.
    Savelli G; Maffioli L; Maccauro M; De Deckere E; Bombardieri E
    Q J Nucl Med; 2001 Mar; 45(1):27-37. PubMed ID: 11456373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bone scintigraphy in bone metastases due to prostatic cancer].
    Hidaka H; Ishino Y; Nakayama C; Nakata H; Okamura T
    J UOEH; 1987 Dec; 9(4):369-77. PubMed ID: 3438611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bone scintigraphy in the preoperative determination of the stage of breast cancer].
    Denisov LE; Iarygin LM; Ermolaeva EV; Zhuravleva LI
    Med Radiol (Mosk); 1984 Jul; 29(7):5-8. PubMed ID: 6087080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The tumor markers CEA, TPA and CA 19-9 and ferritin and osteocalcin in follow-up studies in breast cancer].
    Schatz C; von Lieven H; Mulders M; Rowold J; Stracke H; Müller H; Grebe SF; Schatz H
    Wien Klin Wochenschr; 1985 Dec; 97(23):873-9. PubMed ID: 3878042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Whole-body bone scintigraphy in the diagnosis and follow-up of the evolution of breast cancer].
    Muşat E; Stefănescu C; Rusu V
    Rev Med Chir Soc Med Nat Iasi; 1999; 103(1-2):163-9. PubMed ID: 10756905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technetium-99m MDP scintigraphy. An insensitive tool for the detection of bone marrow metastases.
    Gulenchyn KY; Papoff W
    Clin Nucl Med; 1987 Jan; 12(1):45-6. PubMed ID: 3815996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Is bone scan useful in patients with breast cancer localized on the basis of clinical examination. 143 cases (author's transl)].
    Stines J; Stalars J; Dartois D; Chardot C
    Bull Cancer; 1980; 67(3):319-23. PubMed ID: 7407430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.